Replies to post #217077 on Biotech Values

[JohnWayne]

BMY / 227: woof. Better than a wholly negative result, but that’s going to be tough commercially.

[DewDiligence]

BMY raised 2018 non-GAAP EPS guidance to $3.35-3.45 (from the prior range of $3.15-3.30):

https://www.businesswire.com/news/home/20180426005207/en

A lower-than expected tax rate (17-18% vs prior guidance of 20%) and a higher-than-expected currency benefit are the main reasons for the change.